http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Song, Byung-Cheol,Cui, Xiu Ji,Cho, Yoo-Kyung,Choi, Eun Kwang,Hyun, Soyoung,Song, Hyun Joo,Kim, Heung Up Elsevier 2009 HEPATOLOGY RESEARCH Vol.39 No.11
<P>In endemic areas of hepatitis B virus (HBV) infection, lamivudine-induced hepatitis B e-antigen (HBeAg) loss is not durable. We developed a scoring system to predict the relapse after lamivudine-induced HBeAg loss.</P>
Song, Byung-Cheol,Cui, Xiu Ji,Shin, Jung Woo,Park, Neung Hwa,Cho, Yoo-Kyung,Song, Hyun Joo,Hyun, Soyoung,Jeong, Seung Uk,Choi, Eun Kwang,Kim, Heung Up S. Karger AG 2010 Intervirology Vol.53 No.4
<P><I>Objective:</I> In vitro studies showed that mutations in the basal core promoter (BCP) or precore (PC) region restore the replication inefficiency of the lamivudine-resistant mutant. The aim of this study was to clarify the effect of molecular characteristics on the antiviral response to adefovir in patients with lamivudine-resistant chronic hepatitis B (CHB). <I>Methods:</I> Sixty-six lamivudine-resistant patients who were treated with adefovir monotherapy were studied. Sequences of BCP, PC region and reverse transcriptase were determined before adefovir therapy. In patients with virologic breakthrough, reverse transcriptase sequencing was performed. <I>Results:</I> The cumulative probabilities of virologic response were 23.3, 46, 52.7 and 59.5% at years 1, 2, 3 and 4, respectively. PC mutation, the absence of compensatory mutations (rtL80I/V or rtV173L), and a decrease in serum hepatitis B virus (HBV) DNA by 3 log or greater at 6 months were independent predictors of virologic response. The cumulative probabilities of virologic breakthrough were 0, 12.9, 30.7 and 44.5% at years 1, 2, 3 and 4, respectively. BCP mutation and a less than 3 log decrease in serum HBV DNA at 6 months were 2 independent risk factors for virologic breakthrough. <I>Conclusion:</I> Response to adefovir depends on mutation patterns in the BCP, PC region and reverse transcriptase, and on-treatment decreases in serum HBV DNA in lamivudine-resistant CHB patients.</P><P>Copyright © 2010 S. Karger AG, Basel</P>
Song, Byung-Cheol,Cui, Xiu Ji,Kim, Heung Up,Cho, Yoo-Kyung S. Karger AG 2006 Intervirology Vol.49 No.5
<P><I>Objectives:</I> Despite the pathogenic role of the basal core promoter (BCP) and the precore mutations in chronic hepatitis B virus (HBV) infection, their role in the progression of liver disease is still controversial. We analyzed whether the accumulation of these mutations might enhance the progression of HBV-related chronic liver disease. <I>Methods:</I> Forty consecutive patients at each clinical status were analyzed. Clinical statuses were as follows: HBeAg-positive asymptomatic carrier (HBeAg<SUP>+</SUP> ASC) (defined as HBeAg<SUP>+</SUP>, anti-HBe<SUP>-</SUP>, HBV-DNA<SUP>+</SUP> by hybridization, normal ALT); inactive HBsAg carrier; chronic hepatitis B; liver cirrhosis. The genotype and the BCP/precore regions were determined by PCR using genotype specific primers and direct sequencing, respectively. <I>Results:</I> All patients except one were infected with genotype C. The A to T mutation at nucleotide 1762 and/or G to A mutation at nucleotide 1764 were found in 30% in HBeAg<SUP>+</SUP> ASC, 65.7% in inactive HBsAg carrier, 95% in chronic hepatitis B, and 90% in liver cirrhosis (p < 0.001). The prevalence of the G to A mutation at nucleotide 1896 was 5% in HBeAg<SUP>+</SUP> ASC, 22.5% in inactive HBsAg carrier, 32.5% in chronic hepatitis B, and 50% in liver cirrhosis, respectively (p < 0.001). The T to C/A mutation at nucleotide 1753 in the BCP and G to A mutation at nucleotide 1899 in the precore were more frequent in liver cirrhosis than in the other clinical statuses (p < 0.05). <I>Conclusion:</I> Sequential accumulation of mutations in the BCP/precore has an important role in the progression of HBV-related liver disease.</P><P>Copyright © 2006 S. Karger AG, Basel</P>
제주지역 로타바이러스 위장관염 환아로부터 분리한 A군 로타바이러스의 VP7 Genotypes에 대한 연구
강기수,신경수,김원용,Kang, Ki Soo,Shin, Kyung-Sue,Cui, Xiu Ji,Kim, Wonyong 대한소아소화기영양학회 2006 Pediatric gastroenterology, hepatology & nutrition Vol.9 No.2
Purpose: Efficacy of the new rotavirus vaccines ($Rotarix^{(R)}$, $RotaTeq^{(R)}$) recently developed can be affected by the rotavirus genotypes prevalent in communities. We performed this study to identify the recent distribution of rotavirus genotypes prevalent in Jeju. Methods: Genotyping of human rotaviruses was performed using 81 samples collected from 154 inpatients and outpatients with rotavirus gastroenteritis at Cheju National University Hospital between July 2005 and June 2006. All six (1, 2, 3, 4, 8, 9) G serotypes were identified by amplification of segments of the gene for VP7 using the reverse transcription-polymerase reaction (RT-PCR). Results: The results of RT-PCR for 81 samples were all positive. G typing of the VP7 protein showed that G1 was the most dominant circulating genotype (65.5%) followed by G2 (14.8%), G3 (13.6%), G8 (1.2%), G9 (1.2%), G4 (0%), and a combination of G1/G3 (3.7%). Conclusion: This distribution of rotavirus VP7 genotypes in Jeju is different from that in other domestic areas; the most dominant circulating genotype was G1. 목 적: 최근 새로이 개발된 두 개의 백신(Rotarix, RotaTeq)의 효능은 지역사회에 유행하는 로타바이러스 genotype에 따라 영향을 받을 수 있다. 저자는 제주지역에 유행하는 로타바이러스 genotype의 분포를 알아보고자 하였다. 방 법: 2005년 7월부터 2006년 6월까지 급성 설사로 제주대학교병원 소아과에 내원 또는 입원하여 로타바이러스 위장관염으로 진단 받았던 154명 중 81명에서 대변 검체를 수집하였다. 대변 검체에서 RNA를 추출하여 역전사-중합효소 반응(reverse transcription-polymerase chain reaction, RT-PCR)을 시행하여 로타바이러스 VP7 genes을 증폭하였으며 여섯개(1, 2, 3, 4, 8, 9)의 G 유전형을 확인하였다. 결 과: 역전사-중합효소 반응을 시행한 81개의 대변 검체에서 모두 VP7유전자가 증폭됨을 확인하였다. 이들 검체에서 VP 7 단백의 유전형을 보면 G1이 53예(65.5%)로 가장 많았고 그 다음으로 G2 12예(14.8%), G3 11예(13.6%), G8 1예(1.2%), G9 1예(1.2%), G4 0예(0%) 그리고 G1/G3 혼합형이 3예(3.7%)로 나타났다. 결 론: 제주 지역의 로타바이러스 VP7 genotypes의 분포는 국내의 다른 지역들과 달랐으며, G1 유전형이 가장 흔하게 검출되었다.